CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

The persistence or recurrence of minimal residual disease (MRD) after chemotherapy predicts relapse of B-cell acute lymphoblastic leukemia (B-ALL). CD19-directed chimeric antigen receptor T (CD19 CAR-T) cells have shown promising responses in B-ALL. However, their role in chemotherapy-refractory MRD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Wenyi, Wei, Yunxiong, Cao, Yaqing, Xiao, Xia, Li, Qing, Lyu, Hairong, Jiang, Yili, Zhang, Huan, Li, Xin, Jiang, Yanyu, Meng, Juanxia, Yuan, Ting, Zhu, Haibo, He, Xiaoyuan, Jin, Xin, Sun, Rui, Sui, Tao, Liu, Kaiqi, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571234/
https://www.ncbi.nlm.nih.gov/pubmed/33899130
http://dx.doi.org/10.1007/s00262-021-02941-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571234/
https://www.ncbi.nlm.nih.gov/pubmed/33899130
http://dx.doi.org/10.1007/s00262-021-02941-4

Ejemplares similares